Skip to main content
. 2024 Aug 28;25(17):9345. doi: 10.3390/ijms25179345

Table 1.

Characteristics of patients at baseline.

Characteristic Response, n (%) Overall (n = 22), n (%)
Non-Responder (n = 10) † Responder (n = 12)
Age 66.00 (16.75) 63.00 (28.50) † 66.00 (23.25) †
Gender

  • Female

 7.0 (70.0%) 4.0 (33.3%) 11.0 (50.0%)

  • Male

 3.0 (30.0%) 8.0 (66.7%) 11.0 (50.0%)
BRAF

  • Mutate

 2.0 (20.0%) 5.0 (41.7%) 7.0 (31.8%)

  • Wild-Type

 8.0 (80.0%) 7.0 (58.3%) 15.0 (68.2%)
LDH class

  • 135–225

 3.0 (30.0%) 9.0 (75.0%) 12.0 (54.5%)

  • 240–480

 7.0 (70.0%) 3.0 (25.0%) 10.0 (45.5%)
M-Category

  • M0

 0.0 (0.0%) 0.0 (0.0%) 0.0 (0.0%)

  • M1A

 2.0 (20.0%) 4.0 (33.3%) 6.0 (27.3%)

  • M1B

 1.0 (10.0%) 2.0 (16.7%) 3.0 (13.6%)

  • M1C

 7.0 (70.0%) 6.0 (50.0%) 13.0 (59.1%)
CNS

  • No

 5.0 (50.0%) 12.0 (100.0%) 17.0 (77.3%)

  • Yes

 5.0 (50.0%) 0.0 (0.0%) 5.0 (22.7%)
Treatment

  • Nivolumab

 9.0 (90.0%) 7.0 (58.3%) 16.0 (72.7%)

  • Pembrolizumab

 1.0 (10.0%) 5.0 (41.7%) 6.0 (27.3%)

† Median (IQR). For each tissue sample, 8550 proteins and 770 RNAs were evaluated, with an overlap of 418 genes for which proteomic and transcriptomic data were profiled.